生物制剂治疗皮肤病过程中的矛盾性反应

doi:10.12144/zgmfskin202411812

China Journal of Leprosy and Skin Diseases ›› 2024, Vol. 40 ›› Issue (11): 812-817.doi: 10.12144/zgmfskin202411812

• Reviews • Previous Articles Next Articles

Update of paradoxical reactions during biological agents treatment for dermatosis

XU Fanli^1,2, HU Mingjia^1,2, AO Suiting^1,2, LIU Hong^1,2, ZHANG Furen^1,2

1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China

Online:2024-11-15 Published:2024-10-15

Abstract

XU Fanli, HU Mingjia, AO Suiting, LIU Hong, ZHANG Furen. Update of paradoxical reactions during biological agents treatment for dermatosis[J].China Journal of Leprosy and Skin Diseases, 2024, 40(11): 812-817.

[1]	YANG Yannan, WANG Junhui. Update of biologics and small molecule targeted drugs for the treatment of palmoplantar pustulosis [J]. China Journal of Leprosy and Skin Diseases, 2024, 40(9): 669-673.
[2]	JIAO Yuzhu, YANG Qing. Update of treatment of pyoderma gangrenosum [J]. China Journal of Leprosy and Skin Diseases, 2024, 40(3): 216-220.
[3]	DU Baiyinzi, WANG Huiping, LUO Suju. Efficacy and safety comparation of adalimumab and secukinumab in the treatment of nail psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 26-30.
[4]	DIAO Ziyue, XIA Ruiyuan, YIN Zhiqiang. Update of targeted therapy for localized pustular psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2023, 39(6): 456-460.
[5]	SHI Linli, YAN Shaochen, BI Xinling. Update of paradoxical reactions induced by commonly used biological agents in psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2023, 39(3): 201-205.
[6]	XIE Han, ZENG Tongxiang. Update of biological agents in the treatment of nail psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2023, 39(1): 56-60.
[7]	CHEN Jie, BAO Jun. Application of biological agents used in China in special population with psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2022, 38(3): 199-202.
[8]	MAO Mengmeng, BAI Bingxue. Update of the biological for treating hidradenitis suppurativa [J]. China Journal of Leprosy and Skin Diseases, 2022, 38(1): 56-59.
[9]	SUN Weina, LI Yuzhen. Update of treatment for erythrodermic psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(9): 614-617.
[10]	HU Zhonghui, SUN Qing. Update of biological agents in the treatment of psoriasis comorbidities [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(7): 471-476.
[11]	CHEN Jialin, LIU Guoyan, ZHOU Guizhi, TIAN Hongqing. Pityriasis rubra pilaris successfully treated with secukinumab: a case report and literature review [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(12): 783-786.
[12]	SUN Yonghu, ZHANG Furen. A child with psoriasis successfully treated with interleukin-17A antagonist and literature review [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(1): 30-31.
[13]	XIANG Zhi, MA Yiping, CUI Pangen, CHEN Min. Effect of HLA-Cw6 allele on the efficacy of biological agents for the treatment of psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2019, 35(6): 321-326.
[14]	LIU Huiying, QI Jing, SONG Cuihao, WANG Rui, HUANG Min, XIE Fang, LI Chengxin. Efficacy of infliximab in the long-term treatment of psoriasis arthropathica [J]. China Journal of Leprosy and Skin Diseases, 2019, 35(12): 710-714.
[15]	DAI Huatuo, REN Yunqing. Update on pharmacogenetics of biological agents in the treatment of psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2019, 35(11): 696-700.

Update of paradoxical reactions during biological agents treatment for dermatosis

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10